Encoded Therapeutics Inc.
Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.
$275MSeries F
ParticipantActivity from announced rounds
Farallon Capital Management is the investment manager identified by Encoded Therapeutics and HiBob, with Farallon also used as a short name.
Encoded develops precision gene therapies for neurological disorders. HiBob supplies the Bob people-management platform, while Mirador develops medicines for inflammatory and fibrotic diseases. Their financing events retain the same manager identity without collapsing individual funds.
Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.
HiBob develops Bob, a cloud people-management platform for growing and multinational companies.